[1] In the 1990s, the firm faced increased competition from imported generic products from Asia and those manufactured within the country.
[1] In 1997, the parent company's global re-positioning away from OTC drugs led to a management buyout of majority shares.
The new firm was named Neimeth International Pharmaceuticals, in honor of a Pfizer executive who provided support to the Nigerian operation.
[3] In the middle of 2010s, Neimeth went through a period of losses, at one time, it lost an entire stock of raw materials in a fire incident.
[4] Neimeth's in-house research and development created an herbal remedy for sickle cell crisis management called Ciklavit, with Cajanus cajan as an active ingredient.